Flu Vaccine
-
FDA Approves Moderna’s mRNA-Based Flu Vaccine for Older Adults
The FDA has approved mFlusiva, Moderna’s mRNA-based flu vaccine for adults 50 and older, offering a new tool to combat seasonal influenza.
-
FDA Reverses Course, Will Review Moderna’s mRNA Flu Vaccine
The U.S. Food and Drug Administration has reversed its initial refusal, agreeing to review Moderna’s mRNA flu vaccine application for the 2026/2027 flu season.
-
Influenza A Subclade K: What You Need to Know About the 2025 ‘Super Flu’
Influenza A subclade K has emerged as the dominant flu strain in 2025, raising concerns about vaccine effectiveness and disease severity. Here’s what the data from global health authorities reveals about this evolving virus.